Approval Background

The European Medicines Agency reviewed the clinical efficacy and safety of pertuzumab (brand name Pohardi) and granted formal approval on April 23, 2026. The indication was granted because the therapy demonstrated additional benefit over existing treatments for HER2‑positive breast cancer. Clinical trial data supported tumor growth inhibition and an improvement in overall survival.

Positioning Relative to Competing Drugs

Pertuzumab employs a differentiated mechanism of action—dual receptor blockade—that sets it apart from other HER2‑targeted agents. This provides patients with a new therapeutic option and suggests efficacy even in cases where prior HER2 therapies have failed. The product will compete with other agents within the same therapeutic class.

Reimbursement and Market Entry Challenges

Health systems across Europe will evaluate reimbursement for the new oncology product cautiously. Demonstrating both therapeutic benefit and cost‑effectiveness is essential for smooth reimbursement adoption. Consequently, the sponsor must continue to generate real‑world evidence and conduct health‑economic analyses to support pricing and reimbursement negotiations.

Market Size and Expected Impact

HER2‑positive breast cancer patients represent a defined proportion of the overall cancer population in Europe. The market potential for pertuzumab is therefore substantial. Although the exact market size is not disclosed in the source, the sales performance of existing HER2 therapies suggests that pertuzumab could become a significant growth driver.